Press releases
- Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
- Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
- Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
- Head-to-head Superiority to High-dose Dulaglutide: Innovent's First Phase 3 Clinical Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints
- Innovent Receives NMPA Breakthrough Therapy Designation for IBI343(Anti-Claudin18.2 ADC)as Monotherapy for Advanced Gastric Cancer
- Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO)
- Innovent to Present Clinical Data of Multiple Novel Molecules at the 2024 ASCO Annual Meeting
- Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO)
- Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting
- Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
More ▼
Key statistics
On Friday, Innovent Biologics Inc (1801:HKG.HS) closed at 35.20, 28.94% above the 52 week low of 27.30 set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 36.20 |
---|---|
High | 36.80 |
Low | 34.90 |
Bid | 35.10 |
Offer | 35.20 |
Previous close | 35.25 |
Average volume | 6.54m |
---|---|
Shares outstanding | 1.63bn |
Free float | 1.51bn |
P/E (TTM) | -- |
Market cap | 57.27bn HKD |
EPS (TTM) | -0.7045 HKD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼